Table 2.

Multivariable adjusted¹ OR and 95% CI for invasive breast cancer defined by the status of each individual receptor with lifetime recreational physical activity

Average exercise activity (annual MET hour/week)	No. of participants			OR (95% CI)
	Controls	Receptor negative cases	Receptor positive cases	Receptor negative cases vs. controls	Receptor positive cases vs. controls	Receptor negative vs. receptor positive
Cases sub-grouped by ER status
Inactive	500	136	171	Referent	Referent	Referent
≤2.2	373	76	132	0.78 (0.57–1.07)	0.95 (0.72–1.25)	0.79 (0.54–1.15)
2.3–6.6	369	102	148	1.02 (0.75–1.38)	1.03 (0.78–1.35)	0.98 (0.68–1.40)
6.7–15.1	374	88	127	0.85 (0.62–1.17)	0.83 (0.63–1.10)	1.00 (0.68–1.47)
≥15.2	396	100	115	0.91 (0.67–1.24)	0.73 (0.55–0.98)	1.29 (0.88–1.89)
Trend P-value				0.67	0.03	0.14
Homogeneity of trends for case–control comparison				P = 0.19
Cases sub-grouped by PR status
Inactive	500	148	159	Referent	Referent	Referent
≤2.2	373	91	117	0.87 (0.65–1.18)	0.88 (0.67–1.17)	0.95 (0.65–1.37)
2.3–6.6	369	107	143	1.00 (0.74–1.34)	1.04 (0.79–1.38)	0.92 (0.65–1.31)
6.7–15.1	374	90	125	0.80 (0.59–1.10)	0.86 (0.65–1.15)	0.91 (0.62–1.32)
≥15.2	396	97	118	0.81 (0.60–1.10)	0.81 (0.60–1.08)	1.02 (0.70–1.48)
Trend P-value				0.15	0.17	0.94
Homogeneity of trends for case–control comparison				P = 0.91
Cases sub-grouped by HER2 status
Inactive	500	258	49	Referent	Referent	Referent
≤2.2	373	169	39	0.83 (0.65–1.06)	1.14 (0.72–1.78)	0.75 (0.46-1.21)
2.3–6.6	369	201	49	0.96 (0.75–1.21)	1.38 (0.89–2.13)	0.73 (0.46-1.16)
6.7–15.1	374	173	42	0.77 (0.60–0.99)	1.18 (0.75–1.87)	0.61 (0.38-1.00)
≥15.2	396	178	37	0.77 (0.60–0.99)	0.98 (0.61–1.58)	0.75 (0.45-1.24)
Trend P-value				0.04	0.93	0.14
Homogeneity of trends for case–control comparison				P = 0.23
Cases sub-grouped by p53 status
Inactive	500	213	94	Referent	Referent	Referent
≤2.2	373	149	59	0.88 (0.68–1.14)	0.89 (0.62–1.27)	1.03 (0.68–1.54)
2.3–6.6	369	185	65	1.08 (0.84–1.39)	0.91 (0.63–1.30)	1.21 (0.82–1.80)
6.7–15.1	374	164	51	0.91 (0.70–1.18)	0.67 (0.46–0.98)	1.43 (0.93–2.19)
≥15.2	396	150	65	0.81 (0.62–1.06)	0.81 (0.56–1.16)	0.96 (0.64–1.46)
Trend P-value				0.20	0.11	0.59
Homogeneity of trends for case–control comparison				P = 0.50

OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

¹Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, parity, a four-category variable combining menopausal status and hormone therapy use, body mass index, and the duration of oral contraceptive use.